That theory is about to undergo a critical test in a class action by indirect investors in, you guessed it, Theranos. Last month, shareholder lawyers at Hagens Berman Sobol Shapiro and Robbins Geller Rudman & Dowd filed a motion to certify a class of more than 200 investors who plunked down money in funds that owned shares of Theranos.